Compare coverage — 2 reports
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| The Hill | FDA warns of rare 'eye stroke' risk from GLP-1 drugs |
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with t |
0m | thehill.com | First Page headline | ||
| Ars Technica | FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss |
The risk appears small and data is mixed, but FDA wants patients to be aware. |
17h | arstechnica.com | Latest |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Coverage analysis
PageNews compared 2 reports of this event against health measures. Each score describes the language one report used, not whether it was right.
What this coverage raises
- Unresolved questions 1 of 2 reports
How many of the reports below framed this event in each of those terms, and how strongly. It records what publishers wrote about, not what will happen — PageNews makes no forecast and has no model of any of these.
What each report emphasised
- Ars Technica more uncertainty than the other reports here
Where the reports diverged most
Measured by PageNews from the headline and the publisher’s own summary, not from the full articles. Scores describe word choice and emphasis; the percentage beside each is confidence, which is separate from the score and lower when there was less text to read. How this is measured.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.